Caplin Point Laboratories' (NSE:CAPLIPOINT, BOM:524742) recorded a rise in its consolidated attributable profit to 1.53 billion Indian rupees in the fiscal first quarter ended June 30, against 1.24 billion rupees a year ago.
Earnings per share climbed to 20.03 rupees compared with 16.24 rupees a year earlier, the pharmaceutical company said in a filing to the Indian stock exchanges on Thursday.
Revenue from operations in fiscal Q1 also increased to 5.10 billion rupees from 4.59 billion rupees a year ago.
The company's shares were up over 3% in recent trade.